{"id":138468,"date":"2026-07-31T19:00:11","date_gmt":"2026-07-31T19:00:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/138468\/"},"modified":"2026-07-31T19:00:11","modified_gmt":"2026-07-31T19:00:11","slug":"eli-lilly-stock-has-skyrocketed-novo-nordisk-has-crashed-1-number-explains-why-theyre-not-even-close-anymore-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/138468\/","title":{"rendered":"Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They’re Not Even Close Anymore."},"content":{"rendered":"\n

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are far and away the heavyweights in the global market for GLP-1 drugs<\/a>, which effectively treat both type 2 diabetes and obesity. <\/p>\n

And that market is exploding, particularly for obesity drugs. The global market for obesity medicines reached $66 billion in 2025. Bloomberg predicts it will hit $120 billion by 2030. <\/p>\n

Missed Nvidia in 2009? This Rare Signal Is Flashing Again.\u00a0In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia.\u00a0For the first time in years, that same “Total Conviction” signal is flashing for a company 1\/100th the size of Nvidia.\u00a0Continue \u00bb<\/a> <\/p>\n

Yet Lilly’s share price is up 13.4% this year and 58% over the past 52 weeks, while Novo Nordisk shares are up just 0.4% this year and down 5% over the past 52 weeks. Since July 2024, Novo has plummeted 62%. <\/p>\n

What explains the divergence, with Lilly soaring and Novo collapsing? <\/p>\n

I would point to one number to explain it: market share in the obesity market, which is expected to grow faster than the diabetes drug market. The two drug companies collectively control about 87% of global prescription obesity drug revenue. <\/p>\n

\"A<\/a> Image source: Getty Images. <\/p>\n

But Lilly<\/a> is currently dominant in that market, with a majority 60% share, primarily driven by the popularity and efficacy of its Zepbound GLP-1 obesity drug. <\/p>\n

That’s not to say things can’t change. Until recently, most GLP-1 drugs were delivered via injectables (i.e., needles). This spring, Novo Nordisk introduced its obesity drug Wegovy in pill form, and it’s off to a very fast start. As a result, the Danish firm revised its sales and profit forecasts higher. <\/p>\n

So, stay tuned. The GLP-1 race is far from over, and both firms are committed to winning. <\/p>\n

Should you buy stock in Eli Lilly right now? <\/p>\n

Before you buy stock in\u00a0Eli Lilly, consider this: <\/p>\n

The Motley Fool\u00a0Stock Advisor\u00a0analyst team just identified what they believe are the\u00a010 best stocks<\/a>\u00a0for investors to buy now\u2026 and\u00a0Eli Lilly\u00a0wasn’t one of them.\u00a0The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years. <\/p>\n

Consider when\u00a0Netflix\u00a0made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation,\u00a0you’d have $394,601!*\u00a0Or\u00a0when\u00a0Nvidia\u00a0made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation,\u00a0you’d have $1,197,093!* <\/p>\n

That performance is why people listen. With a track record of\u00a0beating the S&P 500 by 4x,\u00a0Stock Advisor\u00a0offers a distinct advantage. Don’t miss the latest top 10 list, available with\u00a0Stock Advisor, and join an investing community built for the long haul. <\/p>\n","protected":false},"excerpt":{"rendered":"Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are far and away the heavyweights in the global…\n","protected":false},"author":2,"featured_media":138469,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[276,24070,272,278,357,2142],"class_list":["post-138468","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-eli-lilly","tag-global-market","tag-novo-nordisk","tag-nyse","tag-obesity","tag-type-2-diabetes"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117016135371364276","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/138468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=138468"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/138468\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/138469"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=138468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=138468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=138468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}